TLX(Telix Pharmaceuticals Limited) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 |
|---|---|---|---|
| 营业收入 | $110.91M | $333.59M | $515.87M |
| 毛利润 | $65.76M | $208.69M | $335.70M |
| 营业利润 | −$63.69M | $10.51M | $54.10M |
| 净利润 | −$72.11M | $3.46M | $32.88M |
| 经营现金流 | −$44.32M | $15.85M | $28.34M |
| 自由现金流 | −$49.19M | $9.43M | $18.91M |
| 摊薄每股收益 | $-23.21 | $1.07 | $9.52 |